In draft guidance published today healthcare guidance body NICE has recommended simeprevir sodium (Olysio, Janssen) as a treatment option for some people with chronic hepatitis C.

The draft guidance recommends simeprevir, in combination with peginterferon alfa and ribavirin as an option for treating genotype 1 chronic hepatitis C in adults.

Hepatitis C is a virus that infects the liver. It is spread by contact with infected blood, for instance by using contaminated needles for injecting drugs or sharing razors or toothbrushes. The virus can cause inflammation of, and damage to the liver, preventing it from working properly.

For more details, go to: https://www.nice.org.uk/News/Press-and-Media/nice-consults-on-draft-guidance-on-the-drug-simeprevir-olysio-for-treating-hepatitis-c